Antiparkinson's Disease Drugs

Correct Answer

C — Cholinesterase inhibitor approved for Parkinson's disease dementia

Rationale

Rivastigmine is classified as a cholinesterase inhibitor — a drug that blocks acetylcholinesterase to increase acetylcholine availability in the synaptic cleft. It is the only cholinesterase inhibitor with approval from the Food and Drug Administration specifically for Parkinson's disease dementia, which distinguishes it from donepezil, used off-label for this indication. Rivastigmine is available as an oral capsule and as a transdermal patch. It is not a dopamine agonist, an anticholinergic agent, or a monoamine oxidase B inhibitor.

Correct Answer

A — Selective serotonin 5-HT2A inverse agonist

Rationale

Pimavanserin is classified as a selective serotonin 5-HT2A inverse agonist. It is the only drug in this class approved specifically for Parkinson's disease psychosis. Its mechanism is entirely distinct from all other antipsychotics — it has no dopamine receptor activity whatsoever, which means it can reduce hallucinations and delusions without worsening the motor symptoms of Parkinson's disease. Typical antipsychotics block dopamine D2 receptors and are contraindicated in Parkinson's disease. Dopamine agonists stimulate dopamine receptors to treat motor symptoms. Catechol-O-methyltransferase inhibitors extend levodopa plasma half-life by blocking its peripheral metabolism.

Correct Answer

B — Peripherally acting alpha-1 adrenergic agonist

Rationale

Midodrine is classified as a peripherally acting alpha-1 adrenergic agonist. It stimulates alpha-1 receptors in peripheral blood vessels, causing vasoconstriction and raising standing blood pressure. Its peripheral selectivity means it does not cause central stimulant effects. In Parkinson's disease, it is used pharmacologically to treat neurogenic orthostatic hypotension — a common autonomic complication driven by both the disease itself and dopaminergic medications. A mineralocorticoid such as fludrocortisone treats orthostatic hypotension by a different mechanism — expanding plasma volume. A norepinephrine precursor such as droxidopa restores adrenergic vascular tone through precursor conversion. Dopamine agonists treat motor symptoms and can themselves worsen orthostatic hypotension.

Correct Answer

D — Mineralocorticoid

Rationale

Fludrocortisone is classified as a mineralocorticoid — a steroid hormone that acts on mineralocorticoid receptors in the kidneys to promote sodium and water retention, expanding plasma volume. In the context of Parkinson's disease, it is used to treat neurogenic orthostatic hypotension by increasing blood volume and thereby raising standing blood pressure. Midodrine, an alpha-1 adrenergic agonist, treats orthostatic hypotension by causing vasoconstriction rather than volume expansion. Droxidopa, a norepinephrine precursor, raises blood pressure by restoring adrenergic vascular tone. A glucocorticoid such as prednisone acts on glucocorticoid receptors to reduce inflammation and has a different pharmacological profile — fludrocortisone has predominantly mineralocorticoid activity with minimal glucocorticoid effect at therapeutic doses.

Correct Answer

A — Norepinephrine precursor approved for neurogenic orthostatic hypotension

Rationale

Droxidopa is classified as a norepinephrine precursor. It is converted peripherally to norepinephrine, restoring adrenergic vascular tone and raising standing blood pressure in patients with neurogenic orthostatic hypotension — including those with Parkinson's disease whose autonomic nervous system degeneration impairs normal blood pressure regulation. Droxidopa is specifically approved for neurogenic orthostatic hypotension, distinguishing it from midodrine (an alpha-1 agonist that directly stimulates peripheral vessels) and fludrocortisone (a mineralocorticoid that expands plasma volume). Dopamine precursor describes levodopa, which crosses the blood-brain barrier and is converted to dopamine to treat motor symptoms — droxidopa by contrast acts peripherally on the vascular system.

Correct Answer

C — Clozapine and quetiapine

Rationale

Clozapine and quetiapine are both classified as atypical antipsychotics with low dopamine D2 receptor affinity relative to their antipsychotic potency. This low D2 affinity allows them to treat hallucinations and delusions in Parkinson's disease without causing the severe motor deterioration that results from blocking striatal D2 receptors. Haloperidol and risperidone are contraindicated in Parkinson's disease psychosis — haloperidol is a typical antipsychotic with high D2 blockade, and risperidone is an atypical antipsychotic whose high D2 affinity makes it similarly dangerous in this context. Pimavanserin and rivastigmine treat psychosis and dementia respectively but belong to entirely different drug classes. Rasagiline and selegiline are selective monoamine oxidase B inhibitors used to extend dopamine availability in the motor system.

Correct Answer

B — Selective monoamine oxidase B inhibitors leave monoamine oxidase A activity intact in the gut and liver, allowing normal dietary tyramine metabolism

Rationale

Monoamine oxidase exists in two isoforms with different tissue distributions and substrate preferences. Monoamine oxidase A is found predominantly in the gut and liver, where it metabolizes dietary tyramine before it can enter the systemic circulation in significant amounts. Monoamine oxidase B is the predominant brain isoform and preferentially metabolizes dopamine. Selective monoamine oxidase B inhibitors target only the B isoform, leaving monoamine oxidase A activity in the gut and liver intact. Dietary tyramine is therefore metabolized normally, preventing the tyramine-induced norepinephrine release and hypertensive crisis that occurs when both isoforms are blocked. Nonselective monoamine oxidase inhibitors block both isoforms, eliminating the gut and liver protective metabolism of tyramine. Selective monoamine oxidase B inhibitors do not act on tyramine receptors, do not alter their own metabolism in a tyramine-relevant way, and do not affect gastrointestinal motility.

Correct Answer

D — They block conversion of levodopa to 3-O-methyldopa, extending levodopa plasma half-life and reducing competition for blood-brain barrier transport

Rationale

Catechol-O-methyltransferase is an enzyme that methylates levodopa in peripheral tissues, converting it to 3-O-methyldopa — a pharmacologically inactive metabolite. This produces two problems: it shortens the plasma half-life of levodopa by providing an additional route of elimination, and 3-O-methyldopa itself competes with levodopa for entry into the brain via the large neutral amino acid transporter. By blocking catechol-O-methyltransferase, these drugs extend the plasma half-life of levodopa and simultaneously reduce the plasma concentration of 3-O-methyldopa, thereby reducing the competition with levodopa at the blood-brain barrier transporter. Both effects result in more levodopa reaching the brain for longer from each oral dose. Inhibiting aromatic amino acid decarboxylase peripherally is the mechanism of carbidopa, a different drug. Monoamine oxidase B inhibitors target dopamine breakdown inside the brain. Enhancing transporter activity is not the mechanism of catechol-O-methyltransferase inhibitors.

Correct Answer

A — Selegiline is metabolized to amphetamine and methamphetamine, which cause insomnia when present at bedtime

Rationale

Selegiline is irreversibly metabolized to amphetamine and methamphetamine — both pharmacologically active stimulant compounds. These metabolites are the primary clinical liability distinguishing selegiline from rasagiline, which does not produce amphetamine metabolites. When selegiline is taken in the evening, the amphetamine and methamphetamine levels peak during the nighttime hours, causing stimulant-driven insomnia, anxiety, and sometimes palpitations or elevated blood pressure. Restricting dosing to the morning and midday allows the stimulant metabolites to clear sufficiently before bedtime, reducing the insomnia burden. The tyramine interaction risk with selective monoamine oxidase B inhibitors is substantially lower than with nonselective agents and is not the reason for timing restrictions. Circadian-dependent interactions with levodopa and brainstem rapid eye movement sleep effects through monoamine oxidase B inhibition are pharmacologically inaccurate explanations.

Correct Answer

C — Rasagiline is metabolized to aminoindan, a pharmacologically inert compound, rather than the stimulant metabolites produced by selegiline

Rationale

The key pharmacokinetic difference between rasagiline and selegiline lies in their metabolites. Selegiline is metabolized to amphetamine and methamphetamine — pharmacologically active stimulant compounds that cause insomnia, anxiety, palpitations, and elevated blood pressure. Rasagiline is metabolized to aminoindan, which has no pharmacological activity. With no active metabolites, rasagiline produces equivalent monoamine oxidase B inhibition without the stimulant adverse effects that limit selegiline's tolerability. Both drugs cross the blood-brain barrier — their central action is the basis of their therapeutic effect. Both are irreversible inhibitors — reversibility describes safinamide, a different monoamine oxidase B inhibitor. Both selegiline and rasagiline have comparable selectivity for the B isoform; the metabolite difference, rather than isoform selectivity, explains rasagiline's preferred status.

Correct Answer

B — Meperidine

Rationale

Meperidine is absolutely contraindicated with all monoamine oxidase inhibitors, including selective monoamine oxidase B inhibitors such as rasagiline and selegiline. The combination can produce a severe serotonin syndrome-like reaction characterized by hyperthermia, agitation, muscular rigidity, and cardiovascular instability — a potentially fatal interaction. The mechanism involves meperidine's serotonin reuptake inhibiting properties, which when combined with monoamine oxidase inhibition produces excessive serotonergic activity. This contraindication applies to both nonselective and selective monoamine oxidase inhibitors. Among opioid analgesics, morphine, oxycodone, and hydromorphone also require caution in patients taking monoamine oxidase inhibitors, but their risk is lower than meperidine, which is uniquely dangerous due to its additional serotonergic properties. When opioid analgesia is required in a patient on a monoamine oxidase B inhibitor, meperidine must be avoided entirely and other opioids used with careful monitoring.

Correct Answer

D — Entacapone has no antiparkinsonian effect on its own because it only extends the action of levodopa already present in the body

Rationale

Catechol-O-methyltransferase inhibitors work exclusively by blocking the peripheral enzyme that converts levodopa to 3-O-methyldopa, thereby extending levodopa's plasma half-life and increasing the fraction of each levodopa dose that reaches the brain. With no levodopa present, there is nothing for entacapone to protect — it has no mechanism to increase brain dopamine on its own. It does not stimulate dopamine receptors, does not inhibit dopamine breakdown in the brain, and does not release dopamine from surviving neurons. All catechol-O-methyltransferase inhibitors are exclusively adjunctive agents that require levodopa to be therapeutically meaningful. The approval status and dosing duration of entacapone are secondary considerations — the fundamental pharmacological reason monotherapy is impossible is the absence of any independent antiparkinson mechanism.

Correct Answer

A — A benign discoloration caused by excretion of catechol-O-methyltransferase inhibitor metabolites, requiring patient counseling but no clinical intervention

Rationale

Orange urine discoloration is a class-wide adverse effect of all catechol-O-methyltransferase inhibitors — entacapone, tolcapone, and opicapone — caused by the excretion of colored metabolites of these drugs in the urine. It is completely benign and carries no clinical significance beyond its cosmetic appearance. The importance of this adverse effect lies in counseling: patients who are not warned in advance may mistake the orange discoloration for blood in the urine or another sign of serious disease, leading to unnecessary alarm and potentially unnecessary medical evaluation. Informing patients before the first dose prevents this. Hepatotoxicity is an adverse effect specific to tolcapone and is detected by liver function tests — it is not signaled by urine color change. Hemolysis and excessive levodopa accumulation are not mechanisms that produce orange urine in patients on catechol-O-methyltransferase inhibitors.

Correct Answer

C — Tolcapone carries a black box warning for potentially fatal hepatotoxicity, making entacapone the preferred first-line catechol-O-methyltransferase inhibitor

Rationale

Tolcapone carries a black box warning for potentially fatal fulminant hepatic failure — a serious adverse effect not shared by entacapone or opicapone. Because of this hepatotoxicity risk, tolcapone requires regular liver function monitoring and is reserved for patients who have not responded adequately to safer catechol-O-methyltransferase inhibitors. Entacapone, with its excellent safety record and no hepatotoxicity risk, is the standard first-line catechol-O-methyltransferase inhibitor. Tolcapone actually has somewhat greater efficacy than entacapone because it inhibits catechol-O-methyltransferase both peripherally and centrally — but this modest efficacy advantage does not outweigh its hepatotoxicity risk in patients who have alternatives. It is entacapone that must be taken with each levodopa dose due to its short duration of action, while opicapone is the once-daily agent. Orange urine discoloration is a class effect that occurs with all catechol-O-methyltransferase inhibitors equally.

Correct Answer

D — Serotonin syndrome from excessive serotonergic activity when a selective serotonin reuptake inhibitor is combined with a monoamine oxidase B inhibitor

Rationale

Combining a selective serotonin reuptake inhibitor with a monoamine oxidase B inhibitor carries a risk of serotonin syndrome — a potentially serious reaction caused by excessive serotonergic activity in the central and peripheral nervous systems. Selective serotonin reuptake inhibitors block serotonin reuptake, increasing synaptic serotonin. Monoamine oxidase B inhibitors at therapeutic doses have modest effects on serotonin metabolism through residual monoamine oxidase A activity, and when combined with a selective serotonin reuptake inhibitor, serotonin levels can rise to levels that produce symptoms including agitation, tremor, diarrhea, hyperthermia, and in severe cases cardiovascular instability. The combination is not absolutely contraindicated — unlike meperidine, which is — but requires monitoring, particularly with selegiline whose amphetamine metabolites add additional serotonergic and sympathomimetic risk. Tyramine hypertensive crisis is not triggered by antidepressants. Selective serotonin reuptake inhibitors do not block serotonin receptors in the motor system. Hepatotoxicity from metabolite interactions is not a recognized mechanism for this drug combination.

Correct Answer

B — Entacapone increases the bioavailability of each levodopa dose by blocking its peripheral metabolism, resulting in higher peak striatal dopamine levels that produce peak-dose dyskinesias

Rationale

When entacapone is added to a stable carbidopa-levodopa regimen, it blocks the catechol-O-methyltransferase enzyme that would otherwise convert a portion of each oral levodopa dose to 3-O-methyldopa peripherally. More levodopa now reaches the brain from each dose — which is the therapeutic goal for wearing-off — but this also means more dopamine is produced in the striatum at peak levodopa plasma levels than the patient was previously receiving. If the levodopa dose is not reduced to account for this increased bioavailability, the higher peak striatal dopamine levels can produce peak-dose dyskinesias in a patient who previously had none. The management is levodopa dose reduction. Entacapone has no direct receptor activity — it does not stimulate dopamine receptors or inhibit dopamine breakdown in the brain. It does not interfere with carbidopa's mechanism.

Correct Answer

A — The catechol-O-methyltransferase inhibitor increased levodopa bioavailability, raising striatal and mesolimbic dopamine levels and producing dopaminergic neuropsychiatric adverse effects

Rationale

Catechol-O-methyltransferase inhibitors work by blocking the peripheral breakdown of levodopa, increasing the fraction of each dose that reaches the brain. More levodopa in the brain means more dopamine is produced — not only in the nigrostriatal pathway where the therapeutic benefit occurs, but also in the mesolimbic and mesocortical pathways that mediate neuropsychiatric function. A patient who was previously stable on a given levodopa dose may develop hallucinations, confusion, or vivid dreams after a catechol-O-methyltransferase inhibitor is added, because the effective dopamine dose reaching the brain has increased. The management is levodopa dose reduction to bring the total dopaminergic stimulation back to the previously tolerated level. Opicapone acts exclusively in peripheral tissues and does not cross the blood-brain barrier to stimulate receptors directly. It is a catechol-O-methyltransferase inhibitor with no monoamine oxidase B activity. Catechol-O-methyltransferase inhibitors have no effect on acetylcholine metabolism.

Correct Answer

C — Safinamide blocks voltage-gated sodium channels, reducing abnormal glutamate release in the basal ganglia

Rationale

Safinamide is unique among monoamine oxidase B inhibitors in having a second pharmacological mechanism: it blocks voltage-gated sodium channels in basal ganglia neurons, reducing the abnormal glutamate release that contributes to motor fluctuations. In Parkinson's disease, excessive glutamatergic activity in the basal ganglia circuit contributes to the motor instability seen with advanced disease and wearing-off. By reducing this glutamate excess, safinamide provides additional benefit beyond simple dopamine signal extension. This dual mechanism is what distinguishes safinamide from selegiline and rasagiline, which are purely monoamine oxidase B inhibitors. Safinamide is approved only as adjunctive therapy with levodopa — it is not used as monotherapy. It does not block dopamine reuptake transporters, does not stimulate dopamine D3 receptors, and does not inhibit catechol-O-methyltransferase — the last mechanism describes entacapone, tolcapone, and opicapone.